These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 20970607

  • 1. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 2. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, Lavilla FJ.
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [Abstract] [Full Text] [Related]

  • 3. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 4. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 5. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 6. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S, Baroletti SA.
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [Abstract] [Full Text] [Related]

  • 7. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 8. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T, Mis L, Hammond JM.
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [Abstract] [Full Text] [Related]

  • 9. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 10. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C.
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [Abstract] [Full Text] [Related]

  • 11. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 12. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J.
    Nefrologia; 2013 Nov; 33(3):297-300. PubMed ID: 23712219
    [Abstract] [Full Text] [Related]

  • 13. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Nov; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 14. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdtfeger R, Schleuning M.
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [Abstract] [Full Text] [Related]

  • 15. Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation.
    Schleicher C, Palmes D, Utech M, Bonrath E, Senninger N, Schmidt H, Wolters H.
    Transplant Proc; 2010 Sep; 42(7):2572-5. PubMed ID: 20832546
    [Abstract] [Full Text] [Related]

  • 16. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
    Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L.
    Transpl Int; 2007 Apr; 20(4):305-11. PubMed ID: 17326771
    [Abstract] [Full Text] [Related]

  • 17. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 18. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ, Paul E.
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus and everolimus in kidney transplantation.
    Moes DJ, Guchelaar HJ, de Fijter JW.
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [Abstract] [Full Text] [Related]

  • 20. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.